Document is current
Any future updates will be listed below
-
Authors
Markey, Chloe
Croset, Samuel
Woolley, Olivia Ruth
Buldun, Can Martin
Koch, Christian https://orcid.org/0009-0003-4741-4171
Koller, Daniel https://orcid.org/0009-0002-3388-3295
Reker, Daniel https://orcid.org/0000-0003-4789-7380
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM151255)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIH T32 GM133352-4)
- License Information
-
More Information
Article History
Received: 3 August 2023
Accepted: 12 January 2024
First Online: 26 February 2024
Competing interests
: D.R. acts as a consultant to the pharmaceutical and biotechnology industry, as a scientific mentor for the German Accelerator, and serves on the scientific advisory board of Areteia Therapeutics. S.C., O.R.W., C.M.B., C.K. and D.K. are employees of Bellevue Asset Management and members of the investment team BB Biotech, with investments in the biotechnology industry including some of the companies analyzed here—a full list of the portfolio is available at .
